Literature DB >> 25158063

Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.

Jaume Aguero1, Kiyotake Ishikawa2, Lahouaria Hadri2, Carlos Santos-Gallego3, Kenneth Fish2, Nadjib Hammoudi2, Antoine Chaanine2, Samantha Torquato4, Charbel Naim2, Borja Ibanez5, Daniel Pereda5, Ana García-Alvarez5, Valentin Fuster6, Partho P Sengupta3, Jane A Leopold4, Roger J Hajjar2.   

Abstract

In pulmonary hypertension (PH), right ventricular (RV) dysfunction and failure is the main determinant of a poor prognosis. We aimed to characterize RV structural and functional differences during adaptive RV remodeling and progression to RV failure in a large animal model of chronic PH. Postcapillary PH was created surgically in swine (n = 21). After an 8- to 14-wk follow-up, two groups were identified based on the development of overt heart failure (HF): PH-NF (nonfailing, n = 12) and PH-HF (n = 8). In both groups, invasive hemodynamics, pressure-volume relationships, and echocardiography confirmed a significant increase in pulmonary pressures and vascular resistance consistent with PH. Histological analysis also demonstrated distal pulmonary arterial (PA) remodeling in both groups. Diastolic dysfunction, defined by a steeper RV end-diastolic pressure-volume relationship and longitudinal strain, was found in the absence of HF as an early marker of RV remodeling. RV contractility was increased in both groups, and RV-PA coupling was preserved in PH-NF animals but impaired in the PH-HF group. RV hypertrophy was present in PH-HF, although there was evidence of increased RV fibrosis in both PH groups. In the PH-HF group, RV sarcoplasmic reticulum Ca(2+)-ATPase2a expression was decreased, and endoplasmic reticulum stress was increased. Aldosterone levels were also elevated in PH-HF. Thus, in the swine pulmonary vein banding model of chronic postcapillary PH, RV remodeling occurs at the structural, histological, and molecular level. Diastolic dysfunction and fibrosis are present in adaptive RV remodeling, whereas the onset of RV failure is associated with RV-PA uncoupling, defective calcium handling, and hyperaldosteronism.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  SERCA2a; aldosterone; echocardiography; pressure-volume relationships; pulmonary hypertension model; right ventricular remodeling

Mesh:

Substances:

Year:  2014        PMID: 25158063      PMCID: PMC4200337          DOI: 10.1152/ajpheart.00246.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  45 in total

1.  Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications.

Authors:  Holly Geyer; Giuseppe Caracciolo; Haruhiko Abe; Susan Wilansky; Scipione Carerj; Federico Gentile; Hans-Joachim Nesser; Bijoy Khandheria; Jagat Narula; Partho P Sengupta
Journal:  J Am Soc Echocardiogr       Date:  2010-04       Impact factor: 5.251

Review 2.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Lahouaria Hadri; Razmig G Kratlian; Ludovic Benard; Bradley A Maron; Peter Dorfmüller; Dennis Ladage; Christophe Guignabert; Kiyotake Ishikawa; Jaume Aguero; Borja Ibanez; Irene C Turnbull; Erik Kohlbrenner; Lifan Liang; Krisztina Zsebo; Marc Humbert; Jean-Sébastien Hulot; Yoshiaki Kawase; Roger J Hajjar; Jane A Leopold
Journal:  Circulation       Date:  2013-06-26       Impact factor: 29.690

4.  Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension.

Authors:  Yuko Fukuda; Hidekazu Tanaka; Daisuke Sugiyama; Keiko Ryo; Tetsuari Onishi; Hiroyuki Fukuya; Munenobu Nogami; Yoshiharu Ohno; Noriaki Emoto; Hiroya Kawai; Ken-Ichi Hirata
Journal:  J Am Soc Echocardiogr       Date:  2011-07-19       Impact factor: 5.251

5.  Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension.

Authors:  Marlieke L A Haeck; Roderick W C Scherptong; Nina Ajmone Marsan; Eduard R Holman; Martin J Schalij; Jeroen J Bax; Hubert W Vliegen; Victoria Delgado
Journal:  Circ Cardiovasc Imaging       Date:  2012-08-08       Impact factor: 7.792

6.  Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension.

Authors:  Arun Sachdev; Hector R Villarraga; Robert P Frantz; Michael D McGoon; Ju-Feng Hsiao; Joseph F Maalouf; Naser M Ammash; Robert B McCully; Fletcher A Miller; Patricia A Pellikka; Jae K Oh; Garvan C Kane
Journal:  Chest       Date:  2010-12-09       Impact factor: 9.410

7.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Assessment of right ventricular contractile state with the conductance catheter technique in the pig.

Authors:  M L Dickstein; O Yano; H M Spotnitz; D Burkhoff
Journal:  Cardiovasc Res       Date:  1995-06       Impact factor: 10.787

10.  Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database.

Authors:  Kiran K Khush; Gudaye Tasissa; Javed Butler; Dana McGlothlin; Teresa De Marco
Journal:  Am Heart J       Date:  2009-04-23       Impact factor: 4.749

View more
  36 in total

1.  Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension.

Authors:  Benjamin Strauss; Yassine Sassi; Carlos Bueno-Beti; Zeki Ilkan; Nour Raad; Marine Cacheux; Malik Bisserier; Irene C Turnbull; Erik Kohlbrenner; Roger J Hajjar; Lahouaria Hadri; Fadi G Akar
Journal:  J Mol Cell Cardiol       Date:  2018-11-28       Impact factor: 5.000

2.  Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension.

Authors:  Jingbo Dai; Qiyuan Zhou; Haiyang Tang; Tianji Chen; Jing Li; Pradip Raychaudhuri; Jason X-J Yuan; Guofei Zhou
Journal:  Cell Signal       Date:  2018-08-06       Impact factor: 4.315

Review 3.  Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).

Authors:  Bradley A Maron; Roberto F Machado; Larissa Shimoda
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

4.  WIPI1 is a conserved mediator of right ventricular failure.

Authors:  Christos Tzimas; Christoph D Rau; Petra E Buergisser; Gaston Jean-Louis; Katherine Lee; Jeffrey Chukwuneke; Wen Dun; Yibin Wang; Emily J Tsai
Journal:  JCI Insight       Date:  2019-04-25

Review 5.  Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

6.  Right Ventricular Longitudinal Strain Is Depressed in a Bovine Model of Pulmonary Hypertension.

Authors:  Karsten Bartels; R Dale Brown; Daniel L Fox; Todd M Bull; Joseph M Neary; Jennifer L Dorosz; Brian M Fonseca; Kurt R Stenmark
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

7.  Genetic ablation of interleukin-18 does not attenuate hypobaric hypoxia-induced right ventricular hypertrophy.

Authors:  Danielle R Bruns; Peter M Buttrick; Lori A Walker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-08       Impact factor: 5.464

8.  Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

Authors:  Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos G Santos-Gallego; Kenneth M Fish; Erik Kohlbrenner; Nadjib Hammoudi; Changwon Kho; Ahyoung Lee; Borja Ibáñez; Ana García-Alvarez; Krisztina Zsebo; Bradley A Maron; Maria Plataki; Valentin Fuster; Jane A Leopold; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2016-05-03       Impact factor: 24.094

9.  A Zero-Dimensional Model and Protocol for Simulating Patient-Specific Pulmonary Hemodynamics From Limited Clinical Data.

Authors:  Vitaly O Kheyfets; Jamie Dunning; Uyen Truong; Dunbar Ivy; Kendall Hunter; Robin Shandas
Journal:  J Biomech Eng       Date:  2016-12-01       Impact factor: 2.097

10.  Influence of periostin-positive cell-specific Klf5 deletion on aortic thickening in DOCA-salt hypertensive mice.

Authors:  Hirofumi Zempo; Jun-Ichi Suzuki; Masahito Ogawa; Ryo Watanabe; Katsuhito Fujiu; Ichiro Manabe; Simon J Conway; Yoshiaki Taniyama; Ryuichi Morishita; Yasunobu Hirata; Mitsuaki Isobe; Ryozo Nagai
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.